Clinical outcome following stringent discontinuation of dual antiplatelet therapy after 12 months in real-world patients treated with second-generation zotarolimus-eluting resolute and everolimus-eluting xience v stents: 2-year follow-up of the randomized TWENTE trial

Journal of the American College of Cardiology

Volumn 61, Issue 24, 2013, Pages 2406-2416

  Tandjung, Kenneth ^a   Sen, Hanim ^a   Lam, Ming Kai ^a   Basalus, Mounir W Z ^a   Louwerenburg, J W ^a   Stoel, Martin G ^a   Van Houwelingen, K Gert ^a   De Man, Frits H A F ^a   Linssen, Gerard C M ^b   Saïd, Salah A M ^b   Nienhuis, Mark B ^c   Löwik, Marije M ^a   Verhorst, Patrick M J ^a   Van Der Palen, Job ^a,d   Von Birgelen, Clemens ^a,d  

^a MEDISCH SPECTRUM TWENTE   (Netherlands)

^b TWENTEBORG HOSPITAL   (Netherlands)

^c Streekziekenhuis Koningin Beatrix ^*  (Netherlands)

^d UNIVERSITY OF TWENTE   (Netherlands)

Author keywords

drug eluting stent(s); everolimus eluting stent(s); percutaneous coronary intervention; revascularization; zotarolimus eluting stent(s)

Indexed keywords

ACETYLSALICYLIC ACID; ANTITHROMBOCYTIC AGENT; CLOPIDOGREL; EVEROLIMUS; ZOTAROLIMUS;

ADULT; ARTICLE; CONTROLLED STUDY; DRUG ELUTING STENT; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; HEART DEATH; HEART INFARCTION; HEART MUSCLE REVASCULARIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PATIENT SAFETY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SINGLE BLIND PROCEDURE; STENT THROMBOSIS; TREATMENT FAILURE; TREATMENT RESPONSE;

AGED; DRUG-ELUTING STENTS; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; PERCUTANEOUS CORONARY INTERVENTION; PLATELET AGGREGATION INHIBITORS; PROSPECTIVE STUDIES; SIROLIMUS; THROMBOSIS; TIME FACTORS; TREATMENT OUTCOME;

EID: 84878902532     PISSN: 07351097     EISSN: 15583597     Source Type: Journal    
DOI: 10.1016/j.jacc.2013.04.005     Document Type: Article

References (33)

1. G.W. Stone, M. Midei, and W. Newman Comparison of an everolimus-eluting stent and a paclitaxel-eluting stent in patients with coronary artery disease: a randomized trial JAMA 299 2008 1903 1913
2. I.T. Meredith, S. Worthley, and R. Whitbourn Clinical and angiographic results with the next-generation Resolute stent system: a prospective, multicenter, first-in-human trial J Am Coll Cardiol Intv 2 2009 977 985
3. C. von Birgelen, M.W. Basalus, and K. Tandjung A randomized controlled trial in second-generation zotarolimus-eluting Resolute stents versus everolimus-eluting Xience V stents in real-world patients: the TWENTE trial J Am Coll Cardiol 59 2012 1350 1361
4. H. Sen, K. Tandjung, and M.W. Basalus Comparison of eligible non-enrolled patients and the randomised TWENTE trial population treated with Resolute and Xience V drug-eluting stents EuroIntervention 8 2012 664 671
5. P.C. Smits, E. Kedhi, and K.J. Royaards 2-year follow-up of a randomized controlled trial of everolimus- and paclitaxel-eluting stents for coronary revascularization in daily practice. COMPARE (comparison of the everolimus eluting XIENCE-V stent with the paclitaxel eluting TAXUS LIBERTE stent in all-comers: a randomized open label trial) J Am Coll Cardiol 58 2011 11 18
6. L.O. Jensen, P. Thayssen, and E.H. Christiansen 2-year patient-related versus stent-related outcomes: the SORT OUT IV (Scandinavian Organization for Randomized Trials With Clinical Outcome IV) trial J Am Coll Cardiol 60 2012 1140 1147
7. R.A. Byrne, A. Kastrati, and S. Massberg Biodegradable polymer versus permanent polymer drug-eluting stents and everolimus- versus sirolimus-eluting stents in patients with coronary artery disease: 3-year outcomes from a randomized clinical trial J Am Coll Cardiol 58 2011 1325 1331
8. G.W. Stone, A. Rizvi, and K. Sudhir Randomized comparison of everolimus- and paclitaxel-eluting stents. 2-year follow-up from the SPIRIT (Clinical Evaluation of the XIENCE V Everolimus Eluting Coronary Stent System) IV trial J Am Coll Cardiol 58 2011 19 25
9. S. Silber, S. Windecker, P. Vranckx, P.W. Serruys RESOLUTE All Comers investigators Unrestricted randomised use of two new generation drug-eluting coronary stents: 2-year patient-related versus stent-related outcomes from the RESOLUTE All Comers trial Lancet 377 2011 1241 1247
10. J. Wykrzykowska, P. Serruys, and P. Buszman The three year follow-up of the randomised "all-comers" trial of a biodegradable polymer biolimus-eluting stent versus permanent polymer sirolimus-eluting stent (LEADERS) EuroIntervention 7 2011 789 795
11. M.W. Basalus, K. Tandjung, and K.G. van Houwelingen TWENTE Study: The Real-World Endeavor Resolute Versus Xience V Drug-Eluting Stent Study in TWENTE: study design, rationale and objectives Neth Heart J 18 2010 360 364
12. D.E. Cutlip, S. Windecker, and R. Mehran Clinical end points in coronary stent trials: a case for standardized definitions Circulation 115 2007 2344 2351
13. P. Vranckx, D.E. Cutlip, and R. Mehran Myocardial infarction adjudication in contemporary all-comer stent trials: balancing sensitivity and specificity. Addendum to the historical MI definitions used in stent studies EuroIntervention 5 2010 871 874
14. K. Udipi, R.J. Melder, and M. Chen The next generation endeavor resolute stent: role of the BioLinx polymer system EuroIntervention 3 2007 137 139
15. M. Joner, G. Nakazawa, and A.V. Finn Endothelial cell recovery between comparator polymer-based drug-eluting stents J Am Coll Cardiol 52 2008 333 342
16. J.W. Moses, M.B. Leon, and J.J. Popma Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery N Engl J Med 349 2003 1315 1323
17. M.C. Morice, P.W. Serruys, and J.E. Sousa A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization N Engl J Med 346 2002 1773 1780
18. A. Kastrati, J. Mehilli, and J. Pache Analysis of 14 trials comparing sirolimus-eluting stents with bare-metal stents N Engl J Med 356 2007 1030 1039
19. M. Joner, A.V. Finn, and A. Farb Pathology of drug-eluting stents in humans: delayed healing and late thrombotic risk J Am Coll Cardiol 48 2006 193 202
20. G. Nakazawa, A.V. Finn, and M. Joner Delayed arterial healing and increased late stent thrombosis at culprit sites after drug-eluting stent placement for acute myocardial infarction patients: an autopsy study Circulation 118 2008 1138 1145
21. S. Cook, E. Ladich, and G. Nakazawa Correlation of intravascular ultrasound findings with histopathological analysis of thrombus aspirates in patients with very late drug-eluting stent thrombosis Circulation 120 2009 391 399
22. G. Guagliumi, H. Ikejima, and V. Sirbu Impact of drug release kinetics on vascular response to different zotarolimus-eluting stents implanted in patients with long coronary stenoses: the LongOCT study (Optical Coherence Tomography in Long Lesions) J Am Coll Cardiol Intv 4 2011 778 785
23. Y. Onuma, P.W. Serruys, and N. Kukreja Randomized comparison of everolimus- and paclitaxel-eluting stents: pooled analysis of the 2-year clinical follow-up from the SPIRIT II and III trials Eur Heart J 31 2010 1071 1078
24. U. Baber, R. Mehran, and S.K. Sharma Impact of the everolimus-eluting stent on stent thrombosis: a meta-analysis of 13 randomized trials J Am Coll Cardiol 58 2011 1569 1577
25. T. Palmerini, A.J. Kirtane, and P.W. Serruys Stent thrombosis with everolimus-eluting stents: meta-analysis of comparative randomized controlled trials Circ Cardiovasc Interv 5 2012 357 364
26. Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS), European Association for Percutaneous Cardiovascular Interventions (EAPCI) W. Wijns Guidelines on myocardial revascularization Eur Heart J 31 2010 2501 2555
27. G.N. Levine, E.R. Bates, and J.C. Blankenship 2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention. A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions J Am Coll Cardiol 58 2011 e44 122
28. S. Windecker, P.W. Serruys, and S. Wandel Biolimus-eluting stent with biodegradable polymer versus sirolimus-eluting stent with durable polymer for coronary revascularisation (LEADERS): a randomised non-inferiority trial Lancet 372 2008 1163 1173
29. G.W. Stone, A. Rizvi, and W. Newman Everolimus-eluting versus paclitaxel-eluting stents in coronary artery disease N Engl J Med 362 2010 1663 1674
30. L. Mauri, J. Belardi, and S. Silber Duration of dual antiplatelet therapy after drug-eluting stent treatment by geographic region J Am Coll Cardiol 59 2012 E267
31. A.C. Yeung, M.B. Leon, and A. Jain Clinical evaluation of the Resolute zotarolimus-eluting coronary stent system in the treatment of de novo lesions in native coronary arteries: the RESOLUTE US clinical trial J Am Coll Cardiol 57 2011 1778 1783
32. J. Daemen, P. Wenaweser, and K. Tsuchida Early and late coronary stent thrombosis of sirolimus-eluting and paclitaxel-eluting stents in routine clinical practice: data from a large two-institutional cohort study Lancet 369 2007 667 678
33. P.W. Serruys, S. Silber, and S. Garg Comparison of zotarolimus-eluting and everolimus-eluting coronary stents N Engl J Med 363 2010 136 146